» Articles » PMID: 21474589

Anti-phospholipase A₂ Receptor Antibodies Correlate with Clinical Status in Idiopathic Membranous Nephropathy

Overview
Specialty Nephrology
Date 2011 Apr 9
PMID 21474589
Citations 174
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Circulating autoantibodies against the M-type phospholipase A(2) receptor (anti-PLA(2)R) were recently identified in the majority of patients in the United States with idiopathic membranous nephropathy (iMN). The objectives of this study were to assess the prevalence of anti-PLA(2)R in a separate, European cohort of iMN patients and to correlate the presence of anti-PLA(2)R with clinical parameters reflective of disease activity.

Design, Setting, Participants, & Measurements: Anti-PLA(2)R levels were blindly assessed by a Western blot immunoassay in 54 serum samples from 18 patients with iMN collected in various stages of clinical disease. Anti-PLA(2)R levels were correlated with other clinical parameters.

Results: 77.8% of iMN patients in our cohort had antibodies reactive with human PLA(2)R. The antibody levels in these patients correlated strongly with both clinical status and proteinuria (r = 0.73, P < 0.01).

Conclusions: The role of PLA(2)R as a major antigen in iMN was confirmed in an independent, European patient cohort, and levels of circulating anti-PLA(2)R revealed a strong correlation with clinical disease activity. We propose that detection and measurement of these autoantibodies may provide a tool for monitoring of disease activity and treatment efficacy.

Citing Articles

Management and Treatment of Primary Membranous Nephropathy With a Positive PLA2R Marker.

Metuku R, Wynn A, Santos R Cureus. 2025; 16(12):e75057.

PMID: 39759600 PMC: 11698536. DOI: 10.7759/cureus.75057.


Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.

Rovin B, Ronco P, Wetzels J, Adler S, Ayoub I, Zaoui P Kidney Int Rep. 2024; 9(9):2635-2647.

PMID: 39291206 PMC: 11403052. DOI: 10.1016/j.ekir.2024.06.018.


The correlation between anti-phospholipase A2 receptor antibodies and hypercoagulability in patients with idiopathic membranous nephropathy.

Liu Y, Tang Y, Le W, Chen D, Liang D, Xu F Ren Fail. 2024; 46(2):2374448.

PMID: 38973428 PMC: 11232635. DOI: 10.1080/0886022X.2024.2374448.


Ten tips on immunosuppression in primary membranous nephropathy.

Trujillo H, Caravaca-Fontan F, Praga M Clin Kidney J. 2024; 17(6):sfae129.

PMID: 38915435 PMC: 11195618. DOI: 10.1093/ckj/sfae129.


Combined evaluation of glomerular phospholipase A2 receptor and immunoglobulin G subclass in membranous nephropathy.

Ueki K, Tsuchimoto A, Matsukuma Y, Ataka E, Okamoto H, Tanaka S Clin Kidney J. 2024; 17(6):sfae104.

PMID: 38854426 PMC: 11161704. DOI: 10.1093/ckj/sfae104.


References
1.
Beck Jr L, Bonegio R, Lambeau G, Beck D, Powell D, Cummins T . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009; 361(1):11-21. PMC: 2762083. DOI: 10.1056/NEJMoa0810457. View

2.
Branten A, du Buf-Vereijken P, Klasen I, Bosch F, Feith G, Hollander D . Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study. J Am Soc Nephrol. 2004; 16(1):169-74. DOI: 10.1681/ASN.2004040287. View

3.
Beck Jr L, Salant D . Membranous nephropathy: recent travels and new roads ahead. Kidney Int. 2010; 77(9):765-70. DOI: 10.1038/ki.2010.34. View

4.
Debiec H, Ronco P . Fetomaternal alloimmunization with antenatal glomerulopathies. Ann N Y Acad Sci. 2007; 1110:559-66. DOI: 10.1196/annals.1423.060. View

5.
Couser W, Steinmuller D, Stilmant M, Salant D, LOWENSTEIN L . Experimental glomerulonephritis in the isolated perfused rat kidney. J Clin Invest. 1978; 62(6):1275-87. PMC: 371893. DOI: 10.1172/JCI109248. View